A Study Using Tacrolimus, Sirolimus and Bortezomib as Acute Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation
| Status: | Completed |
|---|---|
| Conditions: | Orthopedic, Hematology |
| Therapuetic Areas: | Hematology, Orthopedics / Podiatry |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 8/18/2018 |
| Start Date: | May 16, 2008 |
| End Date: | October 16, 2013 |
A Phase I Study Using Tacrolimus, Sirolimus and Bortezomib as Acute Graft Versus Host Disease Prophylaxis in Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation
The purpose of this study is determine the highest dose of bortezomib, a new drug for
graft-versus host disease prevention, that can be given in combination with sirolimus and
Tacrolimus, without causing severe side effects. This research is being done because there is
no treatment that is 100% effective in preventing graft versus host disease.
The goals of this study are to:
1. Collect peripheral blood stem cells (PBSCs) from donors for transplant.
2. Determine the largest possible dose of bortezomib that can be given to recipients with
various blood cancers in a safe manner.
3. Monitor the recipient for risk of infection or side affects associated with the
transplant.
4. Monitor the recipient for increased immunity following transplantation.
graft-versus host disease prevention, that can be given in combination with sirolimus and
Tacrolimus, without causing severe side effects. This research is being done because there is
no treatment that is 100% effective in preventing graft versus host disease.
The goals of this study are to:
1. Collect peripheral blood stem cells (PBSCs) from donors for transplant.
2. Determine the largest possible dose of bortezomib that can be given to recipients with
various blood cancers in a safe manner.
3. Monitor the recipient for risk of infection or side affects associated with the
transplant.
4. Monitor the recipient for increased immunity following transplantation.
Inclusion Criteria:
- Undergoing myeloablative peripheral blood stem cell transplantation
- Have an HLA matched-related or matched-unrelated donor (9/10 antigen or allelic
mismatch or 10/10 HLA match permitted).
- Hematological malignancy including patients with: AML, ALL, NHL, Hodgkin's Disease,
CLL, CML, MDS and Multiple Myeloma
- Meeting institutional standard criteria for allogeneic PBSC transplantation
Exclusion Criteria:
- Patient has >Grade 2 peripheral neuropathy within 14 days before enrollment.
- History of autologous or allogeneic transplantation
- Evidence of HIV seropositivity
- Evidence of active infection
- Patients with cardiac dysfunction as described in the protocol
- Patients with hypersensitivity to bortezomib, boron or mannitol
We found this trial at
1
site
535 Barnhill Dr
Indianapolis, Indiana 46202
Indianapolis, Indiana 46202
(888) 600-4822
Indiana University Melvin and Bren Simon Cancer Center At the IU Simon Cancer Center, more...
Click here to add this to my saved trials
